Patent · US Active

Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile

US12234239B2 · kind B2 · utility

0Cited by

0References

33Claims

0Family size

Assignee

Elanco US Inc. · US

Inventors

Jingdan Hu · Carmel, US
Timothy Andrew Woods · Edinburgh, US

Key dates

Filing date	Jun 2, 2022
Grant date	Feb 25, 2025
Priority date	—
Expiry date	Jun 2, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.